Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioRestorative Therapies (BRTX) Share-based Compensation (2016 - 2025)

BioRestorative Therapies (BRTX) has disclosed Share-based Compensation for 15 consecutive years, with $399932.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Share-based Compensation rose 40.7% year-over-year to $399932.0, compared with a TTM value of $3.1 million through Sep 2025, down 25.55%, and an annual FY2024 reading of $2.8 million, down 63.86% over the prior year.
  • Share-based Compensation was $399932.0 for Q3 2025 at BioRestorative Therapies, down from $468708.0 in the prior quarter.
  • Across five years, Share-based Compensation topped out at $9.4 million in Q3 2022 and bottomed at $25121.0 in Q1 2021.
  • Average Share-based Compensation over 5 years is $2.1 million, with a median of $1.5 million recorded in 2023.
  • The sharpest move saw Share-based Compensation plummeted 88.68% in 2021, then skyrocketed 13338.57% in 2022.
  • Year by year, Share-based Compensation stood at $5.7 million in 2021, then plummeted by 46.43% to $3.1 million in 2022, then tumbled by 52.12% to $1.5 million in 2023, then plummeted by 88.01% to $175625.0 in 2024, then surged by 127.72% to $399932.0 in 2025.
  • Business Quant data shows Share-based Compensation for BRTX at $399932.0 in Q3 2025, $468708.0 in Q2 2025, and $2.0 million in Q1 2025.